Omnicell (NASDAQ:OMCL) Downgraded to "Buy" Rating by Wall Street Zen

Key Points

• Omnicell has been downgraded by Wall Street Zen from a "strong-buy" to a "buy" rating, indicating a shift in market sentiment towards its stock.
• Analysts have mixed opinions on Omnicell, with target prices ranging from $30 to $62 and a current consensus target price of $45.33.
• The company's recent earnings report showed EPS of $0.45, exceeding expectations, with a revenue of $290.56 million reflecting a 5% year-over-year growth.

Omnicell (NASDAQ:OMCL - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.

A number of other equities analysts have also weighed in on OMCL. Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of "Moderate Buy" and a consensus target price of $45.33.

Omnicell Price Performance

Shares of OMCL stock opened at $30.83 on Friday. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 61.66, a price-to-earnings-growth ratio of 9.06 and a beta of 0.78. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.74. The firm has a fifty day moving average of $29.40 and a 200-day moving average of $32.77.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 EPS. On average, equities research analysts forecast that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Johnson Financial Group Inc. bought a new stake in shares of Omnicell in the 4th quarter valued at about $37,000. GAMMA Investing LLC raised its holdings in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock valued at $50,000 after purchasing an additional 458 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of Omnicell in the 4th quarter valued at about $101,000. Corton Capital Inc. bought a new stake in shares of Omnicell in the 4th quarter valued at about $208,000. Finally, Summit Investment Advisors Inc. raised its holdings in shares of Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after purchasing an additional 307 shares during the period. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.